Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK/STAT pathway

Fig. 2

Dose-dependent effects of tofacitinib on B cell responses in a 6-day HD-PBMC assay. (A) Representative histograms showing CFSE staining of PBMC to assess proliferation of CD19+CD20+ cells for conditions with tofacitinib (Tofa) or control under anti-CD40/IL-21 (left) and CpG/IL-2 stimulation (right). Gates were set using unstimulated cells as control, and percentages of proliferated CD19+CD20+ cells are shown. (B) Representative dot plots showing the percentage of gated plasmablasts (CD27+CD38+) within CD19+CD20+ B cells. Quantification of plasmablast proportions is shown for anti-CD40/IL-21 (left) and CpG/IL-2 stimulation (right). (C) Concentrations of IgG, IgM and IgA in the culture supernatants collected under anti-CD40/IL-21 (left) and CpG/IL-2 (right) stimulation. Graphs display the mean, SD and individual values (*p < 0.05, n = 6 HD)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us